Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. ( (JP:130A) ) has shared an update.
Veritas In Silico Inc. has announced a joint research project with Shimane University aimed at developing a novel drug to suppress Primary Graft Dysfunction (PGD) following lung transplantation. This collaboration leverages VIS’s ibVIS platform to design Antisense Oligonucleotides (ASO) and establish an in vitro evaluation system, while Shimane University will develop a rat model to test the drug’s efficacy. The project, lasting three years, aims to address the significant global demand for effective post-transplant treatments, although it is expected to have minimal immediate impact on VIS’s financial performance.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the biotechnology industry, focusing on drug discovery. The company specializes in developing novel pharmaceuticals using its proprietary drug discovery platform, ibVIS, which integrates digital and drug discovery technologies for mRNA-targeted and nucleic acid-based drug discovery.
Average Trading Volume: 49,172
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.49B
See more insights into 130A stock on TipRanks’ Stock Analysis page.